JP2019516689A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019516689A5 JP2019516689A5 JP2018558200A JP2018558200A JP2019516689A5 JP 2019516689 A5 JP2019516689 A5 JP 2019516689A5 JP 2018558200 A JP2018558200 A JP 2018558200A JP 2018558200 A JP2018558200 A JP 2018558200A JP 2019516689 A5 JP2019516689 A5 JP 2019516689A5
- Authority
- JP
- Japan
- Prior art keywords
- gel composition
- composition according
- gel
- agent
- gelling
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000499 gel Substances 0.000 claims description 84
- 239000000203 mixture Substances 0.000 claims description 62
- 239000003349 gelling agent Substances 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 19
- 239000000032 diagnostic agent Substances 0.000 claims description 17
- 229940039227 diagnostic agent Drugs 0.000 claims description 17
- 230000000069 prophylactic effect Effects 0.000 claims description 17
- AGNTUZCMJBTHOG-UHFFFAOYSA-N 3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]propane-1,2-diol Chemical group OCC(O)COCC(O)COCC(O)CO AGNTUZCMJBTHOG-UHFFFAOYSA-N 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 13
- 239000003960 organic solvent Substances 0.000 claims description 12
- 230000001225 therapeutic effect Effects 0.000 claims description 11
- 238000010438 heat treatment Methods 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 8
- 229930006000 Sucrose Natural products 0.000 claims description 8
- 239000012456 homogeneous solution Substances 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 239000005720 sucrose Substances 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 7
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical group OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- 239000004615 ingredient Substances 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims description 5
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 4
- 239000000017 hydrogel Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 210000004877 mucosa Anatomy 0.000 claims description 4
- 239000002086 nanomaterial Substances 0.000 claims description 4
- -1 ascorbyl decanoate Chemical compound 0.000 claims description 3
- 125000003289 ascorbyl group Chemical group [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 claims description 3
- 210000005178 buccal mucosa Anatomy 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 2
- IQUCNXSZNHPPML-UHFFFAOYSA-N 2-chloro-n-[(4-chlorophenyl)-phenylmethyl]acetamide Chemical compound C=1C=C(Cl)C=CC=1C(NC(=O)CCl)C1=CC=CC=C1 IQUCNXSZNHPPML-UHFFFAOYSA-N 0.000 claims description 2
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims description 2
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims description 2
- 102000004895 Lipoproteins Human genes 0.000 claims description 2
- 108090001030 Lipoproteins Proteins 0.000 claims description 2
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 claims description 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 claims description 2
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 claims description 2
- NENOAJSZZPODGJ-OIMNJJJWSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] octanoate Chemical compound CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NENOAJSZZPODGJ-OIMNJJJWSA-N 0.000 claims description 2
- JPBAVLUULZJFFO-JENHRLMUSA-N [(2s)-2-[(2r)-3,4-dihydroxy-5-oxo-2h-furan-2-yl]-2-hydroxyethyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O JPBAVLUULZJFFO-JENHRLMUSA-N 0.000 claims description 2
- DWKSHXDVQRZSII-SUMWQHHRSA-N [(2s)-2-[(2r)-3,4-dihydroxy-5-oxo-2h-furan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O DWKSHXDVQRZSII-SUMWQHHRSA-N 0.000 claims description 2
- MSKSZMDNKAEBSG-HNAYVOBHSA-N [(2s)-2-[(2r)-3,4-dihydroxy-5-oxo-2h-furan-2-yl]-2-hydroxyethyl] tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O MSKSZMDNKAEBSG-HNAYVOBHSA-N 0.000 claims description 2
- GCSPRLPXTPMSTL-IBDNADADSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)O[C@@]1([C@]2(CO)[C@H]([C@H](O)[C@@H](CO)O2)O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GCSPRLPXTPMSTL-IBDNADADSA-N 0.000 claims description 2
- ZPVGIKNDGJGLCO-VGAMQAOUSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@@]1([C@]2(CO)[C@H]([C@H](O)[C@@H](CO)O2)O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O ZPVGIKNDGJGLCO-VGAMQAOUSA-N 0.000 claims description 2
- SZYSLWCAWVWFLT-UTGHZIEOSA-N [(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]methyl octadecanoate Chemical compound O([C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@]1(COC(=O)CCCCCCCCCCCCCCCCC)O[C@H](CO)[C@@H](O)[C@@H]1O SZYSLWCAWVWFLT-UTGHZIEOSA-N 0.000 claims description 2
- UEYVMVXJVDAGBB-ZHBLIPIOSA-N [(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]methyl tetradecanoate Chemical compound O([C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@]1(COC(=O)CCCCCCCCCCCCC)O[C@H](CO)[C@@H](O)[C@@H]1O UEYVMVXJVDAGBB-ZHBLIPIOSA-N 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 235000010385 ascorbyl palmitate Nutrition 0.000 claims description 2
- 230000036760 body temperature Effects 0.000 claims description 2
- XAPCMTMQBXLDBB-UHFFFAOYSA-N butanoic acid hexyl ester Natural products CCCCCCOC(=O)CCC XAPCMTMQBXLDBB-UHFFFAOYSA-N 0.000 claims description 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 claims description 2
- 239000006185 dispersion Substances 0.000 claims description 2
- 238000005538 encapsulation Methods 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 238000002513 implantation Methods 0.000 claims description 2
- 238000001802 infusion Methods 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 210000004347 intestinal mucosa Anatomy 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- DILOFCBIBDMHAY-UHFFFAOYSA-N methyl 2-(3,4-dimethoxyphenyl)acetate Chemical compound COC(=O)CC1=CC=C(OC)C(OC)=C1 DILOFCBIBDMHAY-UHFFFAOYSA-N 0.000 claims description 2
- 229940105132 myristate Drugs 0.000 claims description 2
- 210000002850 nasal mucosa Anatomy 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 claims description 2
- 229940049964 oleate Drugs 0.000 claims description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 150000003384 small molecules Chemical class 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 229950006451 sorbitan laurate Drugs 0.000 claims description 2
- 235000011067 sorbitan monolaureate Nutrition 0.000 claims description 2
- 239000001587 sorbitan monostearate Substances 0.000 claims description 2
- 235000011076 sorbitan monostearate Nutrition 0.000 claims description 2
- 229940035048 sorbitan monostearate Drugs 0.000 claims description 2
- 229950004959 sorbitan oleate Drugs 0.000 claims description 2
- 125000000185 sucrose group Chemical group 0.000 claims description 2
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 210000002200 mouth mucosa Anatomy 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662332643P | 2016-05-06 | 2016-05-06 | |
| US201662332673P | 2016-05-06 | 2016-05-06 | |
| US62/332,673 | 2016-05-06 | ||
| US62/332,643 | 2016-05-06 | ||
| PCT/US2017/031614 WO2017193138A1 (en) | 2016-05-06 | 2017-05-08 | Self-assembled gel for controlled delivery of thermolabile agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019516689A JP2019516689A (ja) | 2019-06-20 |
| JP2019516689A5 true JP2019516689A5 (https=) | 2020-06-18 |
Family
ID=58709659
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018558200A Pending JP2019516689A (ja) | 2016-05-06 | 2017-05-08 | 生物製剤および不安定な薬剤の制御送達のための自己集合したゲル |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20170319500A1 (https=) |
| EP (1) | EP3452014A1 (https=) |
| JP (1) | JP2019516689A (https=) |
| CA (1) | CA3062885C (https=) |
| WO (1) | WO2017193138A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010033726A2 (en) | 2008-09-17 | 2010-03-25 | The Brigham And Women's Hospital, Inc. | Drug delivery composition comprising a self-assembled gelator |
| JP2013540757A (ja) | 2010-09-24 | 2013-11-07 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | カプセル化された作用物質の放出を制御する能力を有するナノ構造ゲル |
| US10568840B2 (en) | 2016-05-06 | 2020-02-25 | The Brigham And Women's Hospital, Inc. | Self assembled gels for controlled delivery of encapsulated agents to cartilage |
| WO2018144991A1 (en) | 2017-02-03 | 2018-08-09 | The Brigham And Women's Hospital, Inc. | Self-assembled gels formed with anti-retroviral drugs, prodrugs thereof, and pharmaceutical uses thereof |
| EP3621594A1 (en) | 2017-05-08 | 2020-03-18 | Alivio Therapeutics, Inc. | Formulation of nanostructured gels for increased agent loading and adhesion |
| JP2021520352A (ja) * | 2018-04-04 | 2021-08-19 | アリヴィオ セラピューティクス， インコーポレイテッド | 生物製剤の制御送達用の自己組織化ゲルおよびその製造方法 |
| CA3113948A1 (en) * | 2018-10-11 | 2020-04-16 | Alivio Therapeutics, Inc. | Non-injectable hydrogel formulations for smart release |
| CN111821512B (zh) * | 2020-06-19 | 2022-06-14 | 上海大学 | 酶响应释药聚l-谷氨酸/壳聚糖多孔复合微载体、其制备方法及其应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1750671B1 (en) * | 2004-06-03 | 2008-10-15 | Bracco Research S.A. | Liposomal assembly for therapeutic and/or diagnostic use |
| WO2009029543A1 (en) * | 2007-08-24 | 2009-03-05 | Aegis Therapeutics, Llc | Controlled release formulations |
| JP2013540757A (ja) * | 2010-09-24 | 2013-11-07 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | カプセル化された作用物質の放出を制御する能力を有するナノ構造ゲル |
| EP2928513B1 (en) * | 2012-12-07 | 2018-06-06 | Kansas State University Research Foundation | Peptide-albumin hydrogel properties and its applications |
| EP2968135A4 (en) * | 2013-03-14 | 2016-10-26 | Massachusetts Inst Technology | INJECTABLE, MULTILAYER, SELF-COMPOSITE PEPTIDE RUBBER HYDROGELS FOR LONG-TERM AND DELAYED RELEASE OF HUMAN ANTIBODIES |
-
2017
- 2017-05-08 US US15/589,895 patent/US20170319500A1/en not_active Abandoned
- 2017-05-08 WO PCT/US2017/031614 patent/WO2017193138A1/en not_active Ceased
- 2017-05-08 EP EP17723919.1A patent/EP3452014A1/en not_active Withdrawn
- 2017-05-08 JP JP2018558200A patent/JP2019516689A/ja active Pending
- 2017-05-08 CA CA3062885A patent/CA3062885C/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019516689A5 (https=) | ||
| CN107411983B (zh) | 一种水溶性富勒烯外用组合物 | |
| CN104394848B (zh) | 小分子药物的用于胃肠外注射的稳定制剂 | |
| CN105770894B (zh) | 盐酸氨酮戊酸温度敏感型原位凝胶制剂及其制备方法 | |
| CN108158975A (zh) | 氧化石墨烯纳米银特比萘芬抗真菌缓释温敏性凝胶及其制备方法和应用 | |
| CN106265504A (zh) | 一种恩诺沙星纳米混悬液及其制备方法 | |
| CN104887630A (zh) | 一种脂质体包覆脱氢水飞蓟宾磷脂复合物及其制备方法 | |
| CN111956600A (zh) | 治疗结肠炎的一氧化氮原位水凝胶 | |
| CN114404369B (zh) | 一种二氢杨梅素纳米晶及其制备方法和应用 | |
| CN106822908A (zh) | 牛血清白蛋白/聚多巴胺复合微纳米球的制备方法 | |
| CN107412170B (zh) | 一种头孢洛宁纳米混悬剂冻干粉及其制备方法 | |
| CN102579737B (zh) | 一种血竭纳米药物结晶制剂及其制备方法 | |
| CN104840432A (zh) | 一种紫杉烷类长循环纳米粒及其制备方法 | |
| CN110420177A (zh) | 含镇痛药的局部用组合物及其制备方法和用途 | |
| CN104055737B (zh) | 一种盐酸沃尼妙林微球及其制备方法 | |
| JPWO2019195546A5 (https=) | ||
| JP2024528714A (ja) | 分解からの生物学的物質種の保護 | |
| WO2022152021A1 (zh) | 含有难溶性抗肿瘤活性剂的药物组合物及其制备方法 | |
| CN102274158B (zh) | 普卢利沙星脂质体凝胶及其制备方法 | |
| CN111956812B (zh) | 用于超声诊断和治疗胃炎的药物制剂 | |
| CN106727304B (zh) | 一种芬苯达唑混悬剂及其制备方法 | |
| WO2016119114A1 (zh) | 一种葛根素纳米晶胶囊剂及其制备方法 | |
| CN114681613B (zh) | 一种原位成胶化疗免疫药物组合物及其制备方法 | |
| CN104224708A (zh) | 含磁性纳米粒的白藜芦醇复合纳米混悬剂制备方法 | |
| CN102188364B (zh) | 载药类脂微粒的制备方法 |